Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study - Summary - MDSpire
Advertisement
Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study
To investigate the relationship between SGLT2i use and clinical outcomes among patients with concurrent HCM and diabetes in real-world settings, highlighting its potential significance for treatment strategies.
Key Findings:
Patients with HCM on SGLT2i had a significantly lower risk of the primary outcome (HR 0.76, 95% CI 0.67–0.86) during a median follow-up of 3.1 years.
SGLT2i use was associated with reduced all-cause mortality (HR 0.56, 95% CI 0.46–0.68) and fewer HF hospitalizations (HR 0.82, 95% CI 0.72–0.94).
SGLT2i use linked to decreased risk of sudden cardiac death (HR 0.50, 95% CI 0.33–0.77) and ischaemic stroke (HR 0.74, 95% CI 0.62–0.88).
Subgroup analyses showed consistent results across age, sex, and atrial fibrillation.
Interpretation:
The use of SGLT2i is associated with improved clinical outcomes in patients with HCM and concurrent diabetes, indicating a potential therapeutic benefit that could influence treatment guidelines.
Limitations:
The study is observational and may be subject to residual confounding, which could impact the validity of the findings.
Data was derived from a single national database, which may limit generalizability to other populations.
Conclusion:
SGLT2i use is associated with a decreased risk of adverse clinical outcomes among patients with HCM and diabetes, suggesting a promising treatment avenue.
by Mi-Hyang Jung, Jung Sun Cho, So-Young Lee, Jong-Chan Youn, Young Choi, Woo-Baek Chung, Jungkuk Lee, Dongwoo Kang, Woojin Kwon, Tae-Seok Kim, Sang-Hyun Ihm, Hae Ok Jung
